Kinetic Concepts, a USA-based medical technology company with leadership positions in advanced wound care and therapeutic support systems, and LifeCell Corp, which is engaged in innovative tissue repair products for use in reconstructive, urogynecologic and orthopedic surgical procedures, have signed a definitive agreement whereby the former will acquire the latter for $51.00 per share, or $1.7 billion in cash.
The offer represents an 18% premium over the closing price of LifeCell's stock on April 4, and 26% more over the 90-day volume weighted average trading price. The boards of directors of both companies have unanimously approved the transaction.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze